Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness.

Vineesh Indira Chandran Charlotte Wilhelmina Wernberg Mette Munk Enok LauridsenMaria Kløjgaard SkyttheSofie Marchsteiner BendixenFrederik Tibert Larsen Camilla Dalby Hansen Lea Ladegaard GrønkjaerMajken Storm SiersbaekTina Di CaterinoSönke DetlefsenHolger Jon MøllerLars Grøntved Kim RavnskjaerSøren Kragh MoestrupMaja Sofie Thiele Aleksander Krag Jonas Heilskov Graversen

Published in: Hepatology (Baltimore, Md.) (2022)

Plasma TREM2 is a plausible individual biomarker that can rule-in or rule-out the presence of NASH with high accuracy and thus has the potential to reduce the need for liver biopsies and to identify patients who are eligible for clinical trials in NASH.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
randomized controlled trial
patient reported outcomes
risk assessment
human health
phase ii